Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 21, 2016

Amgen receives FDA approval for Kyprolis combination therapy to treat multiple myeloma

The US Food and Drug Administration (FDA) has granted approval for Amgens’ Kyprolis (carfilzomib) combination therapy to treat patients with relapsed or refractory multiple myeloma.

Pharma

The US Food and Drug Administration (FDA) has granted approval for Amgens’ Kyprolis (carfilzomib) combination therapy to treat patients with relapsed or refractory multiple myeloma.

Amgen has received approval for Kyprolis in combination with dexamethasone or with lenalidomide plus dexamethasone to treat patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

Kyprolis has been approved by FDA as a single agent to treat patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Amgen research and development executive vice president Dr Sean Harper said: "Kyprolis is the only approved therapy for relapsed multiple myeloma with proven efficacy as a single agent, doublet and triplet combination that is offered in a variety of doses to meet individual patient needs.

"This new approval supports the use of Kyprolis as a backbone therapy for the management of relapsed multiple myeloma, a difficult-to-treat blood cancer."

"Importantly, this new approval supports the use of Kyprolis as a backbone therapy for the management of relapsed multiple myeloma, a difficult-to-treat blood cancer."

The FDA’s approval was based on results from the Phase III head-to-head Endeavor study, which demonstrated enhanced progression-free survival (PFS) with Kyprolis and dexamethasone compared to Velcade (bortezomib) and dexamethasone.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Last July, the FDA also approved another expanded indication for Kyprolis in combination with lenalidomide and dexamethasone (KRd) to treat patients with multiple myeloma who have received one to three prior lines of therapy.

Kyprolis is a product of Onyx Pharmaceuticals, which is a subsidiary of Amgen.


Image: Histopathological image of multiple myeloma. Photo: courtesy of KGH.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU